MEDICAL MORPHINE MARKET

KEY FINDINGS

• The market expansion is expected to be accelerated by the rise in the prescription of painkillers for various conditions, including cancer, cardiovascular problems, and arthritis. 
• It is anticipated that the rising prevalence of cancer and other diseases, including cardiovascular conditions and others, would have an impact on the worldwide medical morphine market's expansion. 
• The main factor fueling the growth of the medical morphine market value is the rising prevalence of orthopaedic conditions like elbow pain, arthritis, fibromyalgia, and osteoporosis. 
• According to the World Health Organization's February 2021 update, 1.71 billion people worldwide suffer from musculoskeletal problems. The need for its therapies is being driven by the fact that musculoskeletal disorders are one of the main causes of disability worldwide, which is propelling the morphine market's expansion during the study period. 
• The demand for opioids has also been positively impacted by the rising number of people having surgeries, particularly for managing post-operative pain, promoting quick healing, and decreasing patient problems.  
• In addition, generic manufacturers' increased emphasis on the abuse-deterrent formulation (ADF) has led to the development of new opioid variations, which has increased demand for them as potent painkillers. Thus, driving the Medical Morphine market revenue. 
• The North America Medical Morphine Market dominated this market. The presence of major players, the high frequency of chronic diseases in the area, and the developed healthcare infrastructure are only a few of the important aspects responsible for the market's growth. 
• Asia Pacific witnesses rapid expansion in the medical morphine market owing to improving access to pain management, rising incidence of chronic diseases, and growing awareness about palliative care. 
• Fear of opioid dependence and misuse may lead to hesitancy among healthcare providers and patients to use medical morphine. 
• Market players are investing heavily in research and development to expand their product lines, which will grow the Medical Morphine market. 

MEDICAL MORPHINE MARKET INTRODUCTION

Strong opiate morphine is naturally present in opium, a dark-brown substance found in poppies. It is mostly used to treat pain, but it is also frequently consumed recreationally or used to create other illegal opioids. Morphine can be given orally, sublingually, inhaled, injected into a muscle, injected under the skin, intravenously, into the area around the spinal cord, transdermally, or as a rectal suppository. It causes analgesia and modifies perception and emotional reaction to pain by acting directly on the central nervous system.

With repeated use, tolerance and reliance could develop on both a physical and psychological level. It is frequently used for pain from myocardial infarction, kidney stones, and labour pain and can be taken for both acute and chronic pain. When given intravenously, the highest effect is felt after about 20 minutes, and when given orally, the maximum effect is felt after about 60 minutes.

The duration of the effect is between 3 and 7 hours., Low blood pressure, nausea, vomiting, and decreased respiratory effort are a few morphine side effects that could be dangerous. Morphine is abuse-prone and addicting. After prolonged use, opioid withdrawal symptoms could manifest if the dose is decreased. Morphine frequently causes drowsiness, vomiting, and constipation as side effects. It is advised to use morphine with caution if you are pregnant or nursing because it could harm the unborn child.

MEDICAL MORPHINE MARKET SIZE AND FORECAST

The Global Medical Morphine Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

MEDICAL MORPHINE MARKET NEW PRODUCT LAUNCH

An advanced morphine tablet is launched by MS-Contin for use to treat moderate to severe pain, whether it is temporary or chronic. When other painkillers did not work well enough or could not be tolerated, the extended-release capsule and extended-release tablet are used to treat pain that is severe enough to require daily, round-the-clock, long-term opioid medication.

Narcotic analgesics are a class of medications that includes morphine. To treat pain, it works on the central nervous system. The usage of morphine extended-release capsules and tablets is not advised if you just need pain relief for a brief period of time, such as after surgery. Avoid using this medication to treat minor pain or when non-narcotic medications work better. The treatment of occasional or "as needed" discomfort with this medication is not advised.

MEDICAL MORPHINE MARKET NEW PRODUCT DEVELOPMENT

MEDICAL MORPHINE MARKET COMPANY PROFILES

•  MS-Contin
• Kadian
• AVINza
• Morphabond
•  Roxanol SR 
• Oramorph
• Alcaliber S.A Pfizer Inc. 
• Sun Pharmaceutical Industries Ltd. 
• Taj Pharmaceuticals Limited 
• Manus Aktteva Biopharma LLP 
• Mallinckrodt Pharmaceuticals 

MEDICAL MORPHINE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Medical Morphine are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Medical Morphine and key vendor selection criteria
3. Where is the Medical Morphine manufactured? What is the average margin per unit?
4. Market share of Global Medical Morphine market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Medical Morphine in-house
6. key predictions for next 5 years in Global Medical Morphine market
7. Average B-2-B Medical Morphine market price in all segments
8. Latest trends in Medical Morphine market, by every market segment
9. The market size (both volume and value) of the Medical Morphine market in 2024-2030 and every year in between?
10. Production breakup of Medical Morphine market, by suppliers and their OEM relationship